• Thumbnail for Nirmatrelvir
    Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir...
    25 KB (2,009 words) - 15:17, 10 October 2024
  • Thumbnail for Nirmatrelvir/ritonavir
    Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications...
    68 KB (6,125 words) - 04:55, 30 December 2024
  • respiratory syndrome coronavirus 2) inhibitors—class stem –trelvir Ensitrelvir Nirmatrelvir Simnotrelvir Given the specificity of the target of these drugs there...
    12 KB (838 words) - 10:11, 12 August 2024
  • Thumbnail for Ritonavir
    enhance their blood concentration. In December 2021, the combination of nirmatrelvir and ritonavir was granted emergency use authorization by the US Food...
    42 KB (3,597 words) - 13:02, 22 December 2024
  • Thumbnail for COVID-19 drug development
    COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Nirmatrelvir inhibits SARS-CoV-2 main protease, while...
    90 KB (13,197 words) - 04:28, 26 July 2024
  • Thumbnail for Ibuzatrelvir
    second-generation improvement over nirmatrelvir which has a similar chemical structure. One of the disadvantages of nirmatrelvir is that it has low metabolic...
    5 KB (234 words) - 05:42, 2 September 2024
  • Thumbnail for COVID-19 pandemic
    Use (CHMP) approved the oral antiviral protease inhibitor, Paxlovid (nirmatrelvir plus the HIV antiviral ritonavir), to treat adult patients. FDA later...
    368 KB (32,718 words) - 17:52, 31 December 2024
  • Thumbnail for SARS-CoV-2
    December 2021, the United States granted emergency use authorization to Nirmatrelvir/ritonavir for the treatment of the virus; the European Union, United...
    122 KB (12,477 words) - 16:05, 1 December 2024
  • Thumbnail for 3C-like protease
    medication nirmatrelvir (formerly PF-07321332) became commercially available under emergency use authorizations (EUA), as part of the nirmatrelvir/ritonavir...
    17 KB (1,654 words) - 06:47, 28 November 2024
  • Thumbnail for PANORAMIC trial
    The antivirals tested in the study were molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid). Results from the trial showed that for higher risk...
    12 KB (1,087 words) - 03:59, 25 November 2024
  • Nelfinavir HIV Nirmatrelvir/ritonavir (Paxlovid) COVID-19 Pfizer 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir)...
    13 KB (513 words) - 00:20, 23 November 2024
  • moderate symptoms who are in the risk groups[needs update] can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces...
    67 KB (6,361 words) - 23:43, 27 October 2024
  • nutrition products including the oral anti covid medication Molnupiravir & Nirmatrelvir co-packaged with Ritonavir and injectable Remdesivir. Iqbal, Farah K...
    4 KB (256 words) - 13:52, 6 June 2024
  • Thumbnail for COVID-19
    Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces...
    288 KB (33,190 words) - 07:03, 5 January 2025
  • Caffeine/ergotamine — treatment of headaches, such as migraine headache. Nirmatrelvir/ritonavir (Paxlovid) — granted emergency use authorization (EUA) by the...
    7 KB (902 words) - 00:51, 9 October 2024
  • Thumbnail for Jun12682
    from the protease targeted by some other antiviral medications, such as nirmatrelvir/ritonavir, which specifically inhibit the SARS-CoV-2 main protease (Mpro)...
    6 KB (387 words) - 00:03, 26 September 2024
  • Thumbnail for Peptidomimetic
    sequence or identified the screening of compound libraries. For example, Nirmatrelvir is an orally-active small molecule drug derived from lufotrelvir, a modified...
    12 KB (1,365 words) - 13:34, 2 July 2024
  • examining the effectiveness of COVID-19 antivirals including paxlovid (nirmatrelvir/ritonavir) and molnupiravir on acute COVID-19 outcomes and long COVID...
    15 KB (1,483 words) - 04:05, 29 November 2024
  • Thumbnail for GS-441524
    Bao H, Feng H, Mei S, Chen P, et al. (February 2023). "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of...
    22 KB (2,197 words) - 16:56, 17 June 2024
  • Thumbnail for Deuremidevir
    Bao H, Feng H, Mei S, Chen P, et al. (February 2023). "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of...
    6 KB (480 words) - 21:01, 6 November 2024
  • Thumbnail for Simnotrelvir/ritonavir
    the duration of symptoms by a median of 36 hours compared to placebo. Nirmatrelvir/ritonavir Simcere (January 28, 2023). "先诺欣 [先诺特韦片/利托那韦片组合包装 Simnotrelvir...
    8 KB (334 words) - 16:03, 9 August 2024
  • Thumbnail for Viral disease
    Coronaviridae droplet contact coronavirus disease 2019 (COVID-19) Molnupiravir, Nirmatrelvir/ritonavir hand washing covering mouth when coughing or sneezing social...
    36 KB (1,249 words) - 10:35, 10 July 2024
  • Thumbnail for Olgotrelvir
    activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions". Antimicrobial Agents and Chemotherapy. 67...
    10 KB (654 words) - 08:38, 24 November 2024
  • Thumbnail for Ivermectin during the COVID-19 pandemic
    Paxlovid is a combination drug of two small-molecule antiviral compounds (nirmatrelvir and ritonavir) which have no connection to ivermectin. The widespread...
    73 KB (6,796 words) - 13:39, 18 December 2024
  • Sotrovimab Tixagevimab/cilgavimab Tocilizumab Small molecule antivirals Broad-spectrum Ensitrelvir Molnupiravir Remdesivir Co-packaged Nirmatrelvir ritonavir...
    180 KB (23,898 words) - 14:59, 19 August 2024
  • Atazanavir J05AE09 Tipranavir J05AE10 Darunavir J05AE11 Ensitrelvir J05AE30 Nirmatrelvir and ritonavir J05AF01 Zidovudine J05AF02 Didanosine J05AF03 Zalcitabine...
    6 KB (552 words) - 04:04, 23 December 2024
  • Thumbnail for Danyu Lin
    Huang S, Milinovich AT, Sacha GL, Bartley P, Duggal A, Wang X (2023). Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. JAMA...
    18 KB (1,665 words) - 04:39, 11 November 2024
  • Thumbnail for COVID-19 pandemic in Israel
    December 2021, the Israeli Ministry of Health approved the use of Pfizer's Nirmatrelvir/ritonavir for treating COVID-19. The virus begun to rapidly spread after...
    157 KB (16,211 words) - 02:06, 25 October 2024
  • Thumbnail for Hengdian Group
    manufacture the generic version of Pfizer's oral COVID-19 treatment, nirmatrelvir. In July 2022, Hengdian Entertainment, one of the listed companies of...
    15 KB (1,183 words) - 08:33, 31 December 2024
  • Thumbnail for Lufotrelvir
    COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion...
    5 KB (347 words) - 19:59, 20 December 2023